Want to read this article? Try Law360 FREE for seven days
Read the full story now
Already a subscriber? Click here to login
Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
How A Merck Attorney's Lies Torpedoed A $200M Patent Verdict
By Ryan Davis | June 10, 2016, 6:27 PM EDT
On a conference call of drug company officials in March 2004, Merck & Co. Inc. in-house patent prosecutor Philippe Durette assured representatives of Pharamasset Inc. that he could be trusted with information on its “crown jewel” hepatitis C research. That was the first in a series of lies Durette would tell over the course of the next decade that would end with the reversal this week of a $200 million patent infringement verdict Merck won against Gilead Sciences Inc.